

AP1/25: Antithrombotic Agents

This EQA round was accomplished according to the document *EQA Plan 2025*.

Typing conventions: We are using comma as a decimal separator and dates in day.month.year format.

Samples

Three sets of commercial samples were used in this round, each set containing two samples labelled Ax and Bx (where x is the set number). Participants received individual sets according to their orders.

Supervisor's comment

There were 64 participants in this round of which 1 from Poland and 7 from Slovakia.

Assigned values of the CVP type (consensus of all participants) were determined as robust averages of the participants' results.

Long term success rate

You can find the overview of the total success of the participants of this round over last 2 years in the following table. Particular ranges of success are defined in the column headers (percentage of the tests on which the participant reported the correct result). Next 2 lines contain both absolute and relative number of participants who reached the success from the header.

Success		0 %	1 - 74 %	75 - 79 %	80 - 89 %	90 - 94 %	95 - 99 %	100 %
Success in words		unsatisfactory		acceptable	good	very good	excellent	
Count	absolute	1	0	2	8	4	0	49
	relative	1,6 %	-	3,1 %	13 %	6,3 %	-	77 %

Note: You can find your individual success over last 2 years in your result sheet.

Overall success of most participants of this round over the last 2 years is 80 % or higher.

Success rates below 80 % should be considered to be an impulse to improve.

Educational part of the round – uncertainties of measurement results

An overview of the relative combined expanded uncertainties (U_c) reported by the participants can be found in the table below.

Test	Minimum Average Maximum n				Minimum Average Maximum n			
	[%]	[%]	[%]		[%]	[%]	[%]	
Set 1	Sample A1				Sample B1			
(108) Apixaban	0,52	8,7	20	28	0,10	9,9	19	28
Set 2	Sample A2				Sample B2			
(109) Dabigatran	1,5	11	23	19	2,3	13	23	19
Set 3	Sample A3				Sample B3			
(110) Rivaroxaban	0,36	9,5	23	28	1,1	11	24	28

29 participants, almost half of the participants of this round, reported uncertainties of their results.

The average uncertainty values are realistic. However, we still encounter cases where the differences between the minimum and maximum are orders of magnitude. In these cases in particular, we recommend checking whether participants have included all partial uncertainties in the uncertainty calculation and whether they regularly revise (recalculate) their uncertainty estimates, or whether there has been no confusion of units and whether the expanded ($k = 2$) uncertainty has actually been reported.

Scientific supervision: MUDr. Petr Kessler
Hospital Pelhřimov
Department of Hematology and Transfusiology
Slovanského bratrství 710
393 38 Pelhřimov
e-mail: pkessler@hospital-pe.cz

Supplements

As a supplement to this report individual participant who reported the results gain:

Name	Description
Confirmation of attendance Result sheet	The conditions for issuing the relevant document specified in the EQA Plan must be met.
Summary overviews of quantitative results	These documents include a graphical overview of the results in the form of the complex statistics (this includes for each test a Youden plot or histograms, an

AP1/25: Antithrombotic Agents

	overview of the P-score for 2 years history, an overview of the results with uncertainties and summary statistics in graphical form).
--	---

The supplements are identified by their name, EQA round identification and participant code and are intended for the needs of the participant.

If you reported the results in this round, you can find your individual evaluation (reports) in the **Cibule** application (<https://www.eqa.cz/cibule>). After login, select **EQA Results - View** in the menu and then click the **Reports** button for the particular round.

Additional information

The final report, with the exception of the supplements, is public. Further information is freely available to the participants and other professionals at www.sekk.cz, in particular:

- The summary of the results of this round, including this final report.
- The document **EQA Plan** (contains information that applies both to this round and also the EQA in general).
- Explanation of the content of the particular supplements mentioned above.
- Contact to the EQA provider and the EQA coordinator and the list of all supervisors, including contacts.